Expression analysis of CD44 isoforms S and V3, in patients with esophageal squamous cell carcinoma

Document Type: Original Article


1 Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran

2 Department of Genetic, Faculty of science, Shahid Chamran University of Ahvaz, Ahvaz, Iran

3 Medical Genetics Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

4 Pathology Department, Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran


Objective(s):  CD44 is a member of the cell adhesion molecules family. Naturally, CD44S, along with CD44V3 influence the cell motility, migration, and adhesion, while in tumor cells they lead to tumor invasion, progression, and metastasis. The purpose of this research is to evaluate the CD44S and CD44V3 expression in Esophageal Squamous Cell Carcinoma (ESCC) and to reveal their correlations with clinicopathological features of patients.
Materials and Methods:Fresh tumoral and distant tumor-free esophageal tissues were obtained from 50 patients with ESCC. Using quantitative real-time PCR, the expression levels of CD44S and CD44V3 were quantified and compared in both groups of cells. The patients had not received any therapeutic interference, such as chemotherapy or radiation, prior to sampling.
Results:Significant overexpression of CD44S and CD44V3 mRNA was observed in 13 (26.0%, P=0.03) and 11 (22.0%, P=0.007) tumor specimens, respectively. The expression of the genes were significantly correlated not only with each other (P=0.0001), but also with differentiation grade of tumor (P=0.033), stage of tumor progression (P=0.003), and depth of tumor invasion         (P=0.00). In addition, low level of CD44V3 mRNA expression was attended to be associated with tumor invasion.
Conclusion:There is no correlation between CD44S expression with clinicopathological features of patients; however, simultaneous expression of these genes has an important effect on tumorigenesis.


1.Islami F, Kamangar F, Nasrollahzadeh D, Moller H, Boffetta P, Malekzadeh R. Oesophageal cancer in Golestan Province, a high-incidence area in northern Iran - a review. Eur J Cancer 2009; 45:3156-3165.

2.Forghanifard MM, Moghbeli M, Raeisossadati R, Tavassoli A, Mallak AJ, Boroumand-Noughabi S, et al. Role of SALL4 in the progression and metastasis of colorectal cancer. J Biomed Sci 2013; 20:6.

3.Munoz N. Epidemiological aspects of oesophageal cancer. Endoscopy 1993; 25:609-612.

4.Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300.

5. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003; 349:2241-2252.

6.Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist. 2005; 10:590-601.

7. Spechler SJ. Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA 2013; 310:627-636.

8. Attaran-Bandarabadi F, Ziaee AA, Yazdanbod M, Shahpanah M, Setayeshgar A, Nassiri M. Loss of heterozygosity on chromosome 5 in Iranian esophageal cancer patients. Genet Mol Res 2011; 10:2316-2325.

9. Toole BP, Hascall VC. Hyaluronan and tumor growth. Am J Pathol 2002; 161:745-747.

10. Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J Biol Chem 2002; 277:4589-4592.

11. Arpicco S, De Rosa G, Fattal E. Lipid-based nanovectors for targeting of CD44-overexpressing tumor cells. J Drug Deliv 2013; 2013:860780.

12. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 2002; 16:3074-386.

13. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci 2002; 39:527-579.

14. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol Pathol 1999; 52:189-196.

15. Louderbough JM, Schroeder JA. Understanding the dual nature of CD44 in breast cancer progression. Mol Cancer Res  2011; 9:1573-1586.

16. Hiraga T, Ito S, Nakamura H. Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res 2013; 73:4112-4122.

17. Du L, Rao G, Wang H, Li B, Tian W, Cui J, et al. CD44-positive cancer stem cells expressing cellular prion protein contribute to metastatic capacity in colorectal cancer. Cancer Res 2013; 73:2682-294.

18. Joshua B, Kaplan MJ, Doweck I, Pai R, Weissman IL, Prince ME, et al. Frequency of cells expressing CD44, a head and neck cancer stem cell marker: correlation with tumor aggressiveness. Head Neck 2012; 34:42-49.

19. Kuniyasu H, Oue N, Tsutsumi M, Tahara E, Yasui W. Heparan sulfate enhances invasion by human colon carcinoma cell lines through expression of CD44 variant exon 3. Clin Cancer Res. 2001; 7:4067-4072.

20. Gholamin M, Moaven O, Memar B, Farshchian M, Naseh H, Malekzadeh R, et al. Overexpression and interactions of interleukin-10, transforming growth factor beta, and vascular endothelial growth factor in esophageal squamous cell carcinoma. World J Surg 2009; 33:1439-1445.

21. Bourguignon LY, Zhu D, Zhu H. CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression. Front Biosci 1998; 3:d637–d649.

22. Friedrichs K, Kugler G, Franke F, Terpe HJ, Arlt J, Regidor PA, et al. CD44 isoforms in prognosis of breast cancer. Lancet 1995; 345:1237.

23. Ghaffari S, Smadja-Joffe F, Oostendorp R, Levesque JP, Dougherty G, Eaves A, et al. CD44 isoforms in normal and leukemic hematopoiesis. Exp Hematol 1999; 27:978-993.

24. Carinci F, Stabellini G, Calvitti M, Pelucchi S, Targa L, Farina A, et al. CD44 as prognostic factor in oral and oropharyngeal squamous cell carcinoma. J Craniofac Surg 2002; 13:85-89.

25. Lagorce-Pages C, Paraf F, Dubois S, Belghiti J, Flejou JF. Expression of CD44 in premalignant and malignant Barrett's oesophagus. Histopathology 1998; 32:7-14.

26. Takahashi S, Kimoto N, Orita S-i, Cui L, Sakakibara M, Shirai T. Relationship between CD44 expression and differentiation of human prostate adenocarcinomas. Cancer Lett 1998; 129:97–102.

27. Orian-Rousseau Vr. CD44, a therapeutic target for metastasising tumours. European J Cancer 2010; 46:1271-1277.

28. Suzuki H, Yamashiro K. Reduced expression of CD44 v3 and v6 is related to invasion in lung adenocarcinoma. Lung Cancer 2002; 38:137-141.